The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.

Carol M. Kopp edits features on a wide range of subjects for Investopedia, including investing, personal finance, retirement planning, taxes, business management, and career development. Somer G.

A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...

Share on Pinterest An increasing number of people without diabetes are using GLP-1 agonist drugs for weight loss only. Image credit: MarkHatfield/Getty Images. The last few years have seen a marked ...

There’s a new boss at a storied 47-year-old Formula 1 team, and he’s eager to shake things up. He’s been saying that the team is far behind its competition in technology and coordination. And Excel is ...

Patients were intravenously dosed with balstilimab 3 mg/kg once every 2 weeks and zalifrelimab 1 mg/kg once every 6 weeks, for up to 24 months. The primary end point was objective response rate (ORR, ...